Expert Interview
A look at Uplizna (inebilizumab) in patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Ticker(s): HZNPInstitution: McGill University Medical Center
- Assistant professor in the Department of Neurology and Neurosurgery at McGill University.
- Manages 5 patients with NMOSD
- Actively involved in clinical trials relating to MS; practice is focused primarily on the clinical care of patients with MS, with a particular interest in issues related to patient safety and quality improvement.
I understand that NMOSD is a pretty heterogenous disease, but can you kind of walk me through your treatment algorithm? I just kind of want to get an idea of which type of patients get which drugs?
Added By: ben_adminWhat do you perceive as the area of highest unmet need in NMOSD right now? Is it negative symptoms, or better safety profiles, etc?
Added By: ben_adminAre any of your patients still taking any of the off-label medications for NMOSD? What has their response looked like?
- Rituxan (Rituximab)
- CellCept (Mycophenolate Mofetil)
- Imuran (Azathioprine)
- Prednisone
- Methotrexate
If a patient has been taking an off-label drug for a long period of time, when have you made the decision to take patients off of those drugs and onto the FDA approved mediations? What criteria do you use to make this decision?
Added By: ben_adminDo you take genetic variations into consideration when deciding a patients treatment regiment? If so, can you describe the process and what methods you use?
Added By: ben_adminDo you think the Horizon Therapeutics phase 3 data indicating a positive response in patients with genetic variations is strong? Would this analysis change your prescribing habits?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
